MedPath

Pilot Study of efficacy and safety of nalfurafine hydrochloride for jaundice associated pruritus

Not Applicable
Conditions
Pruritus
Registration Number
JPRN-UMIN000033255
Lead Sponsor
Wakayama Medical University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
12
Inclusion Criteria

Not provided

Exclusion Criteria

Patient's consciousness are not alert. Presence of hypersensitivity to nalfurafine hydrochloride and/or fexofenadine hydrochloride. Presence of other dermatosis except for jaundice associated pruritis. Presence of sever organopathy and/or drug allergy. Patients who pregnant or possibility of pregnant, lactating and desire for childbearing. Difficult to ingestion. Ineligible cases are judged by researchers.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Compare with curative effect for pruritus in 2 weeks later medicating between "nalfurafine hydrochloride group" and "fexofenadine hydrochloride group".
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath